AU2003285055A1 - A method for the crystallization of human serum albumin - Google Patents

A method for the crystallization of human serum albumin Download PDF

Info

Publication number
AU2003285055A1
AU2003285055A1 AU2003285055A AU2003285055A AU2003285055A1 AU 2003285055 A1 AU2003285055 A1 AU 2003285055A1 AU 2003285055 A AU2003285055 A AU 2003285055A AU 2003285055 A AU2003285055 A AU 2003285055A AU 2003285055 A1 AU2003285055 A1 AU 2003285055A1
Authority
AU
Australia
Prior art keywords
albumin
crystals
solution
phosphate
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003285055A
Other languages
English (en)
Inventor
Daniel E. Couto
Scott P. Fulton
Sinikka Uotila
Kalevi Visuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAURUS HSA LLC
Original Assignee
TAURUS HSA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAURUS HSA LLC filed Critical TAURUS HSA LLC
Publication of AU2003285055A1 publication Critical patent/AU2003285055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003285055A 2002-11-19 2003-10-28 A method for the crystallization of human serum albumin Abandoned AU2003285055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/300,233 2002-11-19
US10/300,233 US7087719B2 (en) 2002-11-19 2002-11-19 Method for the crystallization of human serum albumin
PCT/US2003/034205 WO2004046311A2 (en) 2002-11-19 2003-10-28 A method for the crystallization of human serum albumin

Publications (1)

Publication Number Publication Date
AU2003285055A1 true AU2003285055A1 (en) 2004-06-15

Family

ID=32297870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003285055A Abandoned AU2003285055A1 (en) 2002-11-19 2003-10-28 A method for the crystallization of human serum albumin

Country Status (8)

Country Link
US (2) US7087719B2 (https=)
EP (1) EP1562991A4 (https=)
JP (1) JP2006506435A (https=)
CN (2) CN1732185A (https=)
AU (1) AU2003285055A1 (https=)
CA (1) CA2506594A1 (https=)
NZ (1) NZ540149A (https=)
WO (1) WO2004046311A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DE69933216T2 (de) * 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US7087719B2 (en) * 2002-11-19 2006-08-08 Gtc Biotherapeutics, Inc. Method for the crystallization of human serum albumin
WO2006068548A1 (en) * 2004-12-21 2006-06-29 Telefonaktiebolaget L M Ericsson (Publ) An arrangement and a method relating to flow of packets in communication systems
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
CN102492027A (zh) * 2011-12-09 2012-06-13 福建省农业科学院农业生物资源研究所 一种提取Bt杀虫蛋白晶体的方法
BR112014027994A2 (pt) * 2012-05-11 2017-06-27 Novartis Ag métodos de cristalização para purificação de anticorpos monoclonais
CN103012581B (zh) * 2012-11-28 2015-11-25 李英俊 制备白蛋白的方法
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
CN104758924A (zh) * 2014-01-06 2015-07-08 河南省医药科学研究院 包含白蛋白的药物组合物及其用途
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105582883B (zh) * 2015-12-25 2017-12-15 北海开元生物科技有限公司 一种活化硅藻土及在血液制品生产中的应用
WO2019240255A1 (ja) * 2018-06-15 2019-12-19 扶桑薬品工業株式会社 生殖補助医療用培地

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4833233A (en) 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE9101149D0 (sv) * 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
US5585466A (en) 1994-12-06 1996-12-17 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Crystals of serum albumin for use in genetic engineering and rational drug design
JP2004536081A (ja) 2001-06-13 2004-12-02 トーラス エイチエスエイ エルエルシー ヒト血清アルブミンの精製
US7087719B2 (en) * 2002-11-19 2006-08-08 Gtc Biotherapeutics, Inc. Method for the crystallization of human serum albumin

Also Published As

Publication number Publication date
US7087719B2 (en) 2006-08-08
WO2004046311A3 (en) 2004-07-29
WO2004046311A2 (en) 2004-06-03
CN1732185A (zh) 2006-02-08
EP1562991A2 (en) 2005-08-17
JP2006506435A (ja) 2006-02-23
CA2506594A1 (en) 2004-06-03
CN101560253A (zh) 2009-10-21
US20060178309A1 (en) 2006-08-10
EP1562991A4 (en) 2006-10-11
NZ540149A (en) 2008-05-30
US20040097710A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
US7087719B2 (en) Method for the crystallization of human serum albumin
Koechlin Preparation and Properties of Serum and Plasma Proteins. XXVIII. The β1-Metal-combining Protein of Human Plasma1a, b
US5756687A (en) Isolation of components of interest from milk
AU2007266951C1 (en) Method for the extraction of one or several proteins present in milk
CA2507817C (en) Il-21 production in prokaryotic hosts
CZ286066B6 (cs) Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu
Sedzik et al. Is myelin basic protein crystallizable?
AU2013258006B2 (en) Crystallization methods for purification of monoclonal antibodies
JPH03103188A (ja) ヒト血清アルブミンの製造方法
JP2006506435A5 (https=)
EP0173215A2 (en) Method for recovering purified growth hormones from genetically engineered microorganisms
JPH10503084A (ja) Ｉｃｅ及びｉｃｅ様合成物並びにその製造方法
RU2733423C1 (ru) Штамм метилотрофных дрожжей Pichia pastoris Yst-HSA-PDI1, продуцирующий рекомбинантный человеческий сывороточный альбумин
JPS62226928A (ja) 臓器機能改善剤
HK1088340A (en) A method for the crystallization of human serum albumin
RU2016899C1 (ru) Способ получения щелочной фосфатазы
KR920008377B1 (ko) 인간 인슐린 유사 성장인자-i의 정제방법
CN112521488A (zh) 牛血清白蛋白的制备方法
ZA200505101B (en) IL-21 production in prokaryotic hosts
PL137975B1 (en) Method of obtaining purified albuminae from placental and extraplacental serum or a ii+iii fluid obtained from placental and extraplacental serum using the cohne process
JPH03219890A (ja) アデニレートキナーゼ融合ペプチドの精製方法
JPH02209895A (ja) 結晶性ヒト顆粒球コロニー刺激因子及びその製造方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application